Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of RSS0343 in Healthy Subjects
NCT07289464Phase 1Completed
- Sponsor
- Reistone Biopharma
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing RSS0343 Tablets Group with RSS0343 Tablets Placebo Group (2 arms). Primary endpoint: Incidence and severity of any adverse events at Day 28. Started Jan 2026; status: completed.
02
Drugs
RSS0343
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT07289464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289464.